ReutersReuters

Linvoseltamab In Combination With Carfilzomib Or Bortezomib Shows Promising Initial Results In Earlier Lines Of Treatment For Relapsed/Refractory Multiple Myeloma

RefinitivMenos de 1 minuto de leitura

Regeneron Pharmaceuticals Inc REGN:

  • LINVOSELTAMAB IN COMBINATION WITH CARFILZOMIB OR BORTEZOMIB SHOWS PROMISING INITIAL RESULTS IN EARLIER LINES OF TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • REGENERON PHARMACEUTICALS INC - 90% OBJECTIVE RESPONSE RATE IN LINVOSELTAMAB AND CARFILZOMIB COMBINATION

Entrar ou criar uma conta gratuita para ler essa notícia